REALRx

Healthy U
Health Choice Utah

PRIOR AUTHORIZATION REQUEST FORM
GONADOTROPIN RELEASE HORMONE AGONISTS AND ANTAGONISTS

Eligard®, Lupron Depot®, Lupron Depot- Ped®, Orilissa®, Supprelin® LA, Zoladex®

For authorization, please answer each question and fax this form PLUS chart notes back to the RealRx Medicaid Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance.

- Healthy U Medicaid: 855-856-5694
- Health Choice Utah: 855-864-1404

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		HCPCS Code:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred product is dependent on indication - see below.

Requested Agent: ☐ Eligard® (leuprolide acetate), ☐ Lupron Depot® (leuprolide acetate), ☐ Lupron Depot- Ped® (leuprolide acetate), ☐ Zoladex® (goserelin), ☐ Orilissa (elagolix) 200 mg

Non-Preferred Agents: ☐ Supprelin® LA (histrelin), ☐ Orilissa (elagolix) 150 mg

Dosing/Frequency:_____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
ADVANCED BREAST CANCER			
1. Does the member have a diagnosis of advanced breast cancer?	☐	☐	**Please provide documentation**
2. Is the member ≥18 years of age?	☐	☐	
3. Is the prescriber an oncologist or endocrinologist?	☐	☐	
4. Is the request for the preferred product Zoladex®?	☐	☐	
CENTRAL PRECOCIOUS PUBERTY			
1. Does the member have a diagnosis of central precocious puberty?	☐	☐	
2. Is the prescriber a pediatric endocrinologist?	☐	☐	
3. Does documentation show baseline LH levels and a LH concentration after GnRH stimulation test?	☐	☐	**Please provide documentation**
4. Does documentation show a baseline LH/FSH ratio and a LH/FSH ratio after GnRH stimulation test ?	☐	☐	**Please provide documentation**
5. Does documentation show the member's baseline bone age is 1 year greater than chronological age?	☐	☐	**Please provide documentation**

6. Does documentation include the member's age at onset of secondary sexual characteristics?	☐	☐	**Please provide documentation**
7. Does documentation show the member's Tanner Stage is ≥ 2?	☐	☐	**Please provide documentation**
8. Have the following diagnoses been ruled out? • Adrenal steroid levels for congenital adrenal hyperplasia • Beta human chorionic gonadotropin level for chorionic gonadotropin secreting tumor • Pelvic/adrenal/testicular ultrasound for steroid secreting tumor • CT scan of head to rule out intracranial tumor	☐	☐	**Please provide documentation**
9. Is the request for the preferred product Lupron Depot-Ped® or Vantas®?	☐	☐	
ENDOMETRIOSIS			
1. For endometriosis with inadequate pain control, is the request for the preferred product Lupron Depot® or Zoladex®? **Imaging confirming the diagnosis is required.**	☐	☐	**Please provide documentation**
2. For endometriosis with inadequate pain control, if the request is for Orilissa® 150 mg, has the member tried and failed Lupron Depot® and Zoladex®? **Imaging confirming the diagnosis is required.**	☐	☐	**Please provide documentation**
3. For endometriosis with dyspareunia and inadequate pain control, is the request for Orilissa® 200 mg? **Imaging confirming the diagnosis is required.**	☐	☐	**Please provide documentation**
4. Is the requesting provider an OB/GYN?	☐	☐	
5. Does documentation show a negative pregnancy test?	☐	☐	**Please provide documentation**
6. Has the member tried and failed at least two of the following: • A combination (estrogen-progesterone) contraceptive taken continuously • A progestin such as DepoProvera® (medroxyprogesterone), Nexplanon® (etonogestrel) or Mirena® (levonorgestrel) • Danazol	☐	☐	**Please provide documentation**
ENDOMETRIAL THINNING			
1. Is the member ≥18 years of age?	☐	☐	
2. Is the requesting provider an OB/GYN?	☐	☐	
3. Is the requested therapy for dysfunctional uterine bleeding prior to endometrial ablation?	☐	☐	**Please provide documentation**
4. Is the request for the preferred product Zoladex®?	☐	☐	
PROSTATE CANCER			
1. Is the member ≥ 18 years of age?	☐	☐	
2. Is the requesting prescriber an oncologist or endocrinologist?	☐	☐	
3. Is the request for the preferred product Eligard®?	☐	☐	
UTERINE LEIOMYOMATA			
1. Is the request for the preferred product Lupron Depot®? **If yes, please complete questions 2 to 4**	☐	☐	
2. Is the member ≥ 18 years of age?	☐	☐	

3. Does the member have a diagnosis of uterine leiomyomata requiring option of surgical intervention?	☐	☐	**Please provide documentation**
4. Does documentation show a clinical estimation of the size of uterus or fibroids?	☐	☐	**Please provide documentation**
5. Is the request for Oriahnn®? **If yes, complete questions 6 to 11**	☐	☐	
6. Is the prescribing provider an OB/GYN, or in consultation with one?	☐	☐	
7. Has the member tried and failed Lupron Depot® AND at least one of the following therapies unless contraindicated? • Combined estrogen-progestin contraceptive • Levonorgestrel-releasing intrauterine systems • Tranexamic acid	☐	☐	**Please provide documentation**
8. Does the member have a clinical diagnosis of uterine leiomyomata (fibroid) as shown by ultrasound?	☐	☐	**Please provide documentation**
9. Does the member have a negative pregnancy test?	☐	☐	**Please provide documentation**
10. Has an endometrial biopsy been performed to rule out endometrial cancer?	☐	☐	**Please provide documentation**
11. Does the member have a t-score > -2.0 at the lumbar spine, total hip, and femoral neck?	☐	☐	**Please provide documentation**
ADOLESCENT GENDER DYSPHORIA: SEE PHARM-HU-150 HORMONE THERAPY FOR GENDER DYSPHORIA			
REAUTHORIZATION			
BREAST CANCER			
1. Does the member have a continued medical need for therapy?	☐	☐	**Please provide documentation**
2. Has the therapy been effective and tolerable?	☐	☐	**Please provide documentation**
CENTRAL PRECOCIOUS PUBERTY			
1. Is the request for reauthorization of therapy?	☐	☐	
2. Does documentation show suppression of increasing LH and FSH levels from baseline?	☐	☐	**Please provide documentation**
3. Has the member's height velocity slowed or stabilized from baseline?	☐	☐	**Please provide documentation**
4. Has the member's bone age slowed from baseline?	☐	☐	**Please provide documentation**
5. Is there a stabilization or regression of the member's Tanner Staging?	☐	☐	**Please provide documentation**
6. Is the member ≤12 years of age if female or ≤13 years of age if male?	☐	☐	
ENDOMETRIOSIS			
1. Does the member have a recurrence of symptoms?	☐	☐	**Please provide documentation**
2. Is the request for Lupron Depot® (leuprolide) or Zoladex® (goserelin) AND has the member received < 12 months of therapy?	☐	☐	**Please provide documentation**
PROSTATE CANCER			
1. Does the member have a continued medical need for therapy?	☐	☐	**Please provide documentation**
2. Has the therapy been effective and tolerable?	☐	☐	**Please provide documentation**
UTERINE LEIOMYOMATA			
1. Does the member have a continued medical need for therapy?	☐	☐	**Please provide documentation**
2. Is the request for Oriahnn® AND has the member received < 24 months of therapy months of therapy?	☐	☐	**Please provide documentation**

ADOLESCENT GENDER DYSPHORIA: SEE PHARM-HU-150 HORMONE THERAPY FOR GENDER DYSPHORIA	
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.	
Additional information:	
PRESCRIBER CERTIFICATION	
I hereby certify this treatment is indicated, necessary and meets the guidelines for use.	
Physician's Signature:	**Date:**

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-MM-026
Origination Date: 01/01/2022
Reviewed/Revised Date: 01/29/2025
Next Review Date: 01/29/2026
Current Effective Date: 02/01/2025

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.